Avillion LLP
www.avillionllp.com
Latest From Avillion LLP
Abingworth Closes 12th Life Sciences Fund ABV VII At $315M
European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII (ABV VII), at $315m, exceeding its $300m target.
Appointments: CRISPR, KSQ Therapeutics, Immunocore, Cellectis, Translate Bio and biOasis
This week's roundup includes CEO appointments by CRISPR Therapeutics and KSQ Therapeutics, in addition to various other board and high-level appointments by Oncorus, Cellectis, BiOasis, Avillion and Revolution Medicines.
Multispecific Approach Could Improve I-O Side Effect Profile, Says Numab
Multispecific antibody therapeutic developer Numab – run by two former Esbatech executives – has come of age with a deal in the IO space that validates its technology. Could this mean bispecific programs have had their day?
Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration
Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
UK
-
UK
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Avillion LLP
- Senior Management
-
Allison Jeynes-Ellis, CEO
John Bradshaw, CFO
Laurence Reilly, CSO
Mark Weinberg, MD, CMO
Kathryn J Gregory, CBO - Contact Info
-
Avillion LLP
Phone: 207470 2458
72 Hammersmith Rd.
Crown House
London, W14 8TH
UK
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice